191 related articles for article (PubMed ID: 17705574)
1. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.
Lynch DM; Slaven T
Clin Drug Investig; 2007; 27(9):661-2. PubMed ID: 17705574
[No Abstract] [Full Text] [Related]
2. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
[TBL] [Abstract][Full Text] [Related]
3. Epoetin alfa and darbepoetin alfa go head to head.
Steensma DP; Loprinzi CL
J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
[No Abstract] [Full Text] [Related]
4. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
[TBL] [Abstract][Full Text] [Related]
5. Epoetin: for better or for worse?
Lancet Oncol; 2004 Jan; 5(1):1. PubMed ID: 14700601
[No Abstract] [Full Text] [Related]
6. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
Itri LM
Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
[No Abstract] [Full Text] [Related]
7. Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy.
Littlewood TJ
Front Radiat Ther Oncol; 2002; 37():34-7. PubMed ID: 11764665
[No Abstract] [Full Text] [Related]
8. Case history. 1: the use of epoetin alfa in delayed anaemia.
Mertelsmann R
Ann Oncol; 1997; 8 Suppl 3():S11-2. PubMed ID: 9341960
[No Abstract] [Full Text] [Related]
9. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.
Meehan KR; Tchekmedyian NS; Smith RE; Kallich J
Clin Drug Investig; 2006; 26(10):593-601. PubMed ID: 17163293
[TBL] [Abstract][Full Text] [Related]
10. Utilisation review of epoetin alfa in cancer patients at a cancer centre in Singapore.
Chan A; Lim LL; Tao M
Singapore Med J; 2009 Apr; 50(4):365-70. PubMed ID: 19421679
[TBL] [Abstract][Full Text] [Related]
11. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
Yang MC
Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
[No Abstract] [Full Text] [Related]
12. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
13. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
Longfield V; Gebhart B; Hayward L
J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548
[No Abstract] [Full Text] [Related]
14. Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update.
Henry DH
Expert Opin Pharmacother; 2005 Feb; 6(2):295-310. PubMed ID: 15757425
[TBL] [Abstract][Full Text] [Related]
15. New oversight put in place for physicians giving anemia drugs to patients with cancer.
Mitka M
JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
[No Abstract] [Full Text] [Related]
16. [Epoetin alfa: recent strategies of use].
Tumori; 1997; 83(6):975-8. PubMed ID: 9537918
[No Abstract] [Full Text] [Related]
17. Case history. 2: The use of epoetin alfa before high-dose chemotherapy.
Mertelsmann R
Ann Oncol; 1997; 8 Suppl 3():S13. PubMed ID: 9341961
[No Abstract] [Full Text] [Related]
18. [Epoetin in cancer patients. Guidelines of the ASCO and the ASH for evidence-based clinical practice].
Del Mastro L; ;
Tumori; 2003; 89(4):1-12. PubMed ID: 14606657
[No Abstract] [Full Text] [Related]
19. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
[TBL] [Abstract][Full Text] [Related]
20. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.
Fallowfield L; Gagnon D; Zagari M; Cella D; Bresnahan B; Littlewood TJ; McNulty P; Gorzegno G; Freund M;
Br J Cancer; 2002 Dec; 87(12):1341-53. PubMed ID: 12454760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
